Genelux Corporation to Participate in a Fireside Chat at H.C. Wainwright Global Investment Conference
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the H.C. Wainwright Global Investment Conference. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat on September 9, 2025, at 2:30 p.m. ET, moderated by Biotech Equity Research Analyst Emily Bodnar.
The company will also conduct one-on-one meetings with institutional investors during the conference. A replay of the session will be available for approximately 90 days on Genelux's IR page.
Genelux Corporation (NASDAQ: GNLX), azienda immuno-oncologica in fase clinica avanzata, ha annunciato la sua partecipazione alla H.C. Wainwright Global Investment Conference. Il CEO e Presidente Thomas Zindrick e il CFO Matt Pulisic parteciperanno a un colloquio informale il 9 settembre 2025 alle 14:30 ET, moderato dall'analista Biotech Equity Research Emily Bodnar.
Durante la conferenza la società terrà inoltre incontri one-to-one con investitori istituzionali. La registrazione della sessione sarà disponibile in replica per circa 90 giorni nella pagina IR di Genelux.
Genelux Corporation (NASDAQ: GNLX), compañía de inmuno-oncología en fase clínica avanzada, ha anunciado su participación en la H.C. Wainwright Global Investment Conference. El CEO y presidente Thomas Zindrick y el CFO Matt Pulisic participarán en una conversación informal el 9 de septiembre de 2025 a las 2:30 p.m. ET, moderada por la analista de Biotech Equity Research Emily Bodnar.
La compañía también mantendrá reuniones individuales con inversores institucionales durante la conferencia. La reproducción de la sesión estará disponible aproximadamente 90 días en la página de IR de Genelux.
Genelux Corporation (NASDAQ: GNLX), 후기 임상 단계의 면역종양학 회사가 H.C. Wainwright 글로벌 인베스트먼트 컨퍼런스에 참여한다고 발표했습니다. CEO 겸 회장 토머스 진드릭(Thomas Zindrick)과 CFO 매트 풀리식(Matt Pulisic)이 바이오텍 이쿼티 리서치 애널리스트 에밀리 보드나(Emily Bodnar)의 사회로 2025년 9월 9일 동부시간 오후 2시 30분에 파이어사이드 챗을 진행합니다.
회사 측은 콘퍼런스 기간 중 기관 투자자들과의 1:1 미팅도 진행할 예정입니다. 해당 세션의 재생 영상은 약 90일간 Genelux의 IR 페이지에서 제공됩니다.
Genelux Corporation (NASDAQ: GNLX), société d'immuno-oncologie en phase clinique avancée, a annoncé sa participation à la H.C. Wainwright Global Investment Conference. Le PDG et président Thomas Zindrick et le directeur financier Matt Pulisic prendront part à un « fireside chat » le 9 septembre 2025 à 14h30 ET, animé par l'analyste Biotech Equity Research Emily Bodnar.
La société tiendra également des réunions individuelles avec des investisseurs institutionnels pendant la conférence. La rediffusion de la session sera disponible pendant environ 90 jours sur la page IR de Genelux.
Genelux Corporation (NASDAQ: GNLX), ein immunonkologisches Unternehmen in späten klinischen Phasen, hat seine Teilnahme an der H.C. Wainwright Global Investment Conference angekündigt. CEO und Chairman Thomas Zindrick sowie CFO Matt Pulisic werden an einem Fireside-Chat am 9. September 2025 um 14:30 Uhr ET teilnehmen, moderiert von der Biotech-Equity-Research-Analystin Emily Bodnar.
Das Unternehmen wird während der Konferenz zudem Einzelgespräche mit institutionellen Investoren führen. Eine Aufzeichnung der Sitzung wird für etwa 90 Tage auf der IR-Seite von Genelux verfügbar sein.
- None.
- None.
WESTLAKE VILLAGE, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that Thomas Zindrick, President, CEO and Chairman of the Board and Matt Pulisic, Chief Financial Officer, will participate in a fireside chat at H.C. Wainwright & Co’s Annual Global Investment Conference on Tuesday, September 9, 2025.
Biotech Equity Research Analyst, Emily Bodnar, will moderate the session which is scheduled to begin at 2:30 p.m. ET. To register for and view the session, please use the link https://journey.ct.events/view/6248b37e-6c86-47e2-8bd2-0e03637b46e4. An archived replay will be available for approximately 90 days following the event on the company’s IR page.
The Company will also attend one-on-one meetings during the conference. Institutional investors interested in arranging a meeting with Genelux management can register to attend the conference or contact genelux@allelecomms.com
About Genelux Corporation
Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician's choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and, VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician's choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux's discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. For more information, please visit www.genelux.com and follow us on Twitter @Genelux_Corp and on LinkedIn.
Investor and Media Contacts
Ankit Bhargava, MD
Allele Communications, LLC
genelux@allelecomms.com
Source: Genelux Corporation
FAQ
When is Genelux (NASDAQ: GNLX) presenting at the H.C. Wainwright Conference?
Who will represent Genelux at the H.C. Wainwright Conference?
How can investors access Genelux's H.C. Wainwright Conference presentation?
How can institutional investors arrange meetings with Genelux management?
